255 related articles for article (PubMed ID: 32763240)
1. A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.
Henn MR; O'Brien EJ; Diao L; Feagan BG; Sandborn WJ; Huttenhower C; Wortman JR; McGovern BH; Wang-Weigand S; Lichter DI; Chafee M; Ford CB; Bernardo P; Zhao P; Simmons S; Tomlinson AD; Cook DN; Pomerantz RJ; Misra BK; Auninš JG; Trucksis M
Gastroenterology; 2021 Jan; 160(1):115-127.e30. PubMed ID: 32763240
[TBL] [Abstract][Full Text] [Related]
2. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial.
Paramsothy S; Kamm MA; Kaakoush NO; Walsh AJ; van den Bogaerde J; Samuel D; Leong RWL; Connor S; Ng W; Paramsothy R; Xuan W; Lin E; Mitchell HM; Borody TJ
Lancet; 2017 Mar; 389(10075):1218-1228. PubMed ID: 28214091
[TBL] [Abstract][Full Text] [Related]
3. Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis.
Paramsothy S; Nielsen S; Kamm MA; Deshpande NP; Faith JJ; Clemente JC; Paramsothy R; Walsh AJ; van den Bogaerde J; Samuel D; Leong RWL; Connor S; Ng W; Lin E; Borody TJ; Wilkins MR; Colombel JF; Mitchell HM; Kaakoush NO
Gastroenterology; 2019 Apr; 156(5):1440-1454.e2. PubMed ID: 30529583
[TBL] [Abstract][Full Text] [Related]
4. SER-109, an Oral Microbiome Therapy for Recurrent
Feuerstadt P; Louie TJ; Lashner B; Wang EEL; Diao L; Bryant JA; Sims M; Kraft CS; Cohen SH; Berenson CS; Korman LY; Ford CB; Litcofsky KD; Lombardo MJ; Wortman JR; Wu H; Auniņš JG; McChalicher CWJ; Winkler JA; McGovern BH; Trucksis M; Henn MR; von Moltke L
N Engl J Med; 2022 Jan; 386(3):220-229. PubMed ID: 35045228
[TBL] [Abstract][Full Text] [Related]
5. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial.
Moayyedi P; Surette MG; Kim PT; Libertucci J; Wolfe M; Onischi C; Armstrong D; Marshall JK; Kassam Z; Reinisch W; Lee CH
Gastroenterology; 2015 Jul; 149(1):102-109.e6. PubMed ID: 25857665
[TBL] [Abstract][Full Text] [Related]
6. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
Haifer C; Paramsothy S; Kaakoush NO; Saikal A; Ghaly S; Yang T; Luu LDW; Borody TJ; Leong RW
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):141-151. PubMed ID: 34863330
[TBL] [Abstract][Full Text] [Related]
7. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
[TBL] [Abstract][Full Text] [Related]
8. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
Sandborn WJ; Peyrin-Biroulet L; Zhang J; Chiorean M; Vermeire S; Lee SD; Kühbacher T; Yacyshyn B; Cabell CH; Naik SU; Klassen P; Panés J
Gastroenterology; 2020 Feb; 158(3):550-561. PubMed ID: 31711921
[TBL] [Abstract][Full Text] [Related]
10. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
Atreya R; Peyrin-Biroulet L; Klymenko A; Augustyn M; Bakulin I; Slankamenac D; Miheller P; Gasbarrini A; Hébuterne X; Arnesson K; Knittel T; Kowalski J; Neurath MF; Sandborn WJ; Reinisch W;
Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1063-1075. PubMed ID: 33031757
[TBL] [Abstract][Full Text] [Related]
11. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
Sandborn WJ; Vermeire S; Peyrin-Biroulet L; Dubinsky MC; Panes J; Yarur A; Ritter T; Baert F; Schreiber S; Sloan S; Cataldi F; Shan K; Rabbat CJ; Chiorean M; Wolf DC; Sands BE; D'Haens G; Danese S; Goetsch M; Feagan BG
Lancet; 2023 Apr; 401(10383):1159-1171. PubMed ID: 36871574
[TBL] [Abstract][Full Text] [Related]
12. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial.
Costello SP; Hughes PA; Waters O; Bryant RV; Vincent AD; Blatchford P; Katsikeros R; Makanyanga J; Campaniello MA; Mavrangelos C; Rosewarne CP; Bickley C; Peters C; Schoeman MN; Conlon MA; Roberts-Thomson IC; Andrews JM
JAMA; 2019 Jan; 321(2):156-164. PubMed ID: 30644982
[TBL] [Abstract][Full Text] [Related]
13. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
Carbonnel F; Colombel JF; Filippi J; Katsanos KH; Peyrin-Biroulet L; Allez M; Nachury M; Novacek G; Danese S; Abitbol V; Bossa F; Moreau J; Bommelaer G; Bourreille A; Fumery M; Roblin X; Reinisch W; Bouhnik Y; Brixi H; Seksik P; Malamut G; Färkkilä M; Coulibaly B; Dewit O; Louis E; Deplanque D; Michetti P; Sarter H; Laharie D; ;
Gastroenterology; 2016 Feb; 150(2):380-8.e4. PubMed ID: 26632520
[TBL] [Abstract][Full Text] [Related]
15. Coconut Water Induces Clinical Remission in Mild to Moderate Ulcerative Colitis: Double-blind Placebo-controlled Trial.
Kedia S; Virmani S; Bajaj A; Markandey M; Singh N; Madan D; Kaushal K; Sahu P; Vuyyuru SK; Kante B; Kumar P; Thomas DM; Mundhra SK; Singh MK; Verma M; Sharma R; Das P; Dash NR; Monga N; Awasthi A; Makharia G; Ahuja V
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1295-1306.e7. PubMed ID: 38278200
[TBL] [Abstract][Full Text] [Related]
16. WITHDRAWN: EFFICACY, SAFETY, AND TOLERABILITY OF OMILANCOR IN A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PATIENTS WITH ULCERATIVE COLITIS.
Leber A; Hontecillas R; Tubau-Juni N; Lichtiger S; Bassaganya-Riera J
Inflamm Bowel Dis; 2022 Jan; 28(Suppl 1):S112. PubMed ID: 35104848
[TBL] [Abstract][Full Text] [Related]
17. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis.
Rossen NG; Fuentes S; van der Spek MJ; Tijssen JG; Hartman JH; Duflou A; Löwenberg M; van den Brink GR; Mathus-Vliegen EM; de Vos WM; Zoetendal EG; D'Haens GR; Ponsioen CY
Gastroenterology; 2015 Jul; 149(1):110-118.e4. PubMed ID: 25836986
[TBL] [Abstract][Full Text] [Related]
18. Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.
Danese S; Neurath MF; Kopoń A; Zakko SF; Simmons TC; Fogel R; Siegel CA; Panaccione R; Zhan X; Usiskin K; Chitkara D
Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2526-2534.e9. PubMed ID: 31926340
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
20. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
Lang A; Salomon N; Wu JC; Kopylov U; Lahat A; Har-Noy O; Ching JY; Cheong PK; Avidan B; Gamus D; Kaimakliotis I; Eliakim R; Ng SC; Ben-Horin S
Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1444-9.e1. PubMed ID: 25724700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
